Horizon Therapeutics Plc Announces New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be presented At ECTRIMS 2023
Portfolio Pulse from Benzinga Newsdesk
Horizon Therapeutics (NASDAQ:HZNP) has announced that new analyses of its drug UPLIZNA will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the FDA, the European Commission, and the Brazilian Health Regulatory Agency for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults.
October 02, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Horizon Therapeutics' announcement of new UPLIZNA analyses could potentially boost investor confidence in the company's product pipeline and its commitment to addressing NMOSD, a rare neuroinflammatory autoimmune disease.
The announcement of new analyses of UPLIZNA, a drug approved for the treatment of NMOSD, demonstrates Horizon Therapeutics' ongoing commitment to research and development in this area. This could potentially boost investor confidence in the company's product pipeline and its ability to address rare diseases, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100